The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis

Pediatr Surg Int. 2013 Feb;29(2):101-19. doi: 10.1007/s00383-012-3239-7. Epub 2012 Dec 29.


Neuroblastoma is a highly heterogeneous tumor accounting for 15 % of all pediatric cancer deaths. Clinical behavior ranges from the spontaneous regression of localized, asymptomatic tumors, as well as metastasized tumors in infants, to rapid progression and resistance to therapy. Genomic amplification of the MYCN oncogene has been used to predict outcome in neuroblastoma for over 30 years, however, recent methodological advances including miRNA and mRNA profiling, comparative genomic hybridization (array-CGH), and whole-genome sequencing have enabled the detailed analysis of the neuroblastoma genome, leading to the identification of new prognostic markers and better patient stratification. In this review, we will describe the main genetic factors responsible for these diverse clinical phenotypes in neuroblastoma, the chronology of their discovery, and the impact on patient prognosis.

Publication types

  • Review

MeSH terms

  • Child
  • Chromosome Deletion
  • Chromosome Mapping / methods
  • Epigenomics / methods*
  • Humans
  • Neuroblastoma / genetics*